-
Mashup Score: 17
Triple-negative breast cancer (TNBC) is a heterogeneous disease and we have previously shown that rapid relapse of TNBC is associated with distinct sociodemographic features. We hypothesized that rapid versus late relapse in TNBC is also defined by distinct …
Source: www.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Leanne Hainsby (@leannehainsby) • Instagram photos and videos - 23 day(s) ago
71K likes, 1,388 comments – leannehainsby on April 21, 2024: “So proud of us. Today, we completed the 2024 London Marathon 🎉🙌🏻 What’s even more amazing than that is that we have (currently…”.
Source: www.instagram.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 29BCTRP Pilot Grants | OSUCCC Breast Cancer - 25 day(s) ago
“Inflammation and Lymphedema” William Carson, Roman Skoracki, and Karen Hock “Tissue Factor (CD142) as a New Target for Antibody-Drug Conjugate Treatment of Triple-Negative Breast Cancer” Zhiwei Hu, Robert Wesolowski, and Kai Johnson “Spatial Association of Tumor Microbes and the Tumor Microenvironment in Breast Cancer Subtypes” Sachin Jhawar and Dan Spakowicz “Effect of a MIND Diet Intervention on DNA Methylation Patterns in Breast Cancer Survivors: Analysis of Patient Specimens from the MIND-BC Pilot
Source: u.osu.eduCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 48Assay Validation of Cell-Free DNA Shallow Whole-Genome Sequencing to Determine Tumor Fraction in Advanced Cancers - 2 month(s) ago
Blood-based liquid biopsy is increasingly used in clinical care of patients with cancer, and fraction of tumor-derived DNA in circulation (tumor fraction; TFx) has demonstrated clinical validity across multiple cancer types. To determine TFx, shallow whole-genome sequencing of cell-free DNA (cfDNA) can be performed from a single blood sample, using an established computational pipeline (ichorCNA), without prior knowledge of tumor mutations, in a highly cost-effective manner. We describe assay validation of this approach to facilitate broad clinical application, including evaluation of assay sensitivity, precision, repeatability, reproducibility, pre-analytic factors, and DNA quality/quantity.
Source: www.jmdjournal.orgCategories: General Medicine News, Hem/OncsTweet-
ctDNA 'tumor fraction' is a simple concept & remains a relevant biomarker in diverse cancers. @broadinstitute Genomics Platform & @StoverLab validated shallow WGS assay sensitivity, precision, repeat-/reproducibility, & pre-analytic factors - in @JMDiagn https://t.co/drKNlYegDQ https://t.co/Eyq1yK7mdU
-
-
Mashup Score: 36Pelotonia | Profile - 3 month(s) ago
Pelotonia is a community that is determined to see an end to cancer. Together, we’ve saved countless lives. Help us save more.
Source: www.pelotonia.orgCategories: General Medicine News, Hem/OncsTweet-
Honored to speak at @Pelotonia 2024 'high rollers' kickoff for AMAZING riders 🚴🏻♀️ who raise >$5000 to #EndCancer! I was so inspired...that I am joining them! If you are moved to support my journey: https://t.co/ARkBxr8mnw 📷: Signing up w @David_Cohn_MD @DeanBradfordMD @Zihai https://t.co/qO2m0Oc5eY
-
-
Mashup Score: 22
Breast cancer experts from Ohio State and invited speakers will bring you the latest insights and practical guidance as presented at the 2023 San Antonio Breast Cancer Symposium.
Source: cancer.osu.eduCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 22
Breast cancer experts from Ohio State and invited speakers will bring you the latest insights and practical guidance as presented at the 2023 San Antonio Breast Cancer Symposium.
Source: cancer.osu.eduCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients with Cancer - 5 month(s) ago
Background Tumor genomic testing (TGT) has become standard-of-care for most patients with advanced/metastatic cancer. Despite established guidelines, patient education prior to TGT is variable or frequently omitted. The purpose of this study was to evaluate the impact of a concise (3-4 minute) video for patient education prior to TGT. Methods Based on a quality improvement cycle, an animated video was created to be applicable to any cancer type, incorporating culturally diverse images, available in English and Spanish. Patients undergoing standard-of care TGT were enrolled at a tertiary academic institution and completed validated survey instruments immediately prior to video viewing (T1) and immediately post-viewing (T2). Instruments included: 1) 10-question objective genomic knowledge/understanding; 2) 10-question video message-specific knowledge/recall; 3) 11-question Trust in Physician/Provider; 4) attitudes regarding TGT. The primary objective was change in outcomes from before to
Source: www.medrxiv.orgCategories: General Medicine News, Hem/OncsTweet-
@maryam_lustberg @LeighaSenter And preprint of 150 pt prospective study (NCT05215769) showing that by spending 4 minutes viewing the video, patients have better understanding about: -Potential for incidental germline findings -Risks/benefits of testing -Insurance coverage of testing https://t.co/siz1N6Czu8
-
-
Mashup Score: 5Prospective Decision Analysis Study of Clinical Genomic Testing in Metastatic Breast Cancer: Impact on Outcomes and Patient Perceptions - 5 month(s) ago
To evaluate the impact of targeted DNA sequencing on selection of cancer therapy for patients with metastatic breast cancer (MBC).In this prospective, single-center, single-arm trial, patients with MBC were enrolled within 10 weeks of starting a new therapy. …
Source: www.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 20Tumor Testing: What Do I Need to Know? - 5 month(s) ago
Tumor Genomic TestingFor many patients with cancer, a piece of their tumor or a blood sample (‘liquid biopsy’) is sent to look for mutations in the cancer cells that may impact treatment. Learn more about ‘tumor genomic testing’ below: Copyright © 2023. The Ohio State University. All rights reserved. No part of this video may be reproduced, displayed, modified, or…
Source: www.tumor-testing.comCategories: General Medicine News, Hem/OncsTweet
Disappointing that addition of #immunotherapy did not benefit rapid relapse #tnbc Thanks to @stolaney1 for highlighting @StoverLab work showing primary TNBC that develop rapid relapse highly immune suppressed, perhaps foreshadowing IMpassion132 results: https://t.co/Rs8EdIDMOP https://t.co/Cf98Uw9lQ3